Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation
Ngày 19/05/2020 09:01 | Lượt xem: 28

A study presented yesterday at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time) indicates that the addition of icosapent ethyl to statin therapy in patients with elevated triglycerides and increased cardiovascular risk is associated with reductions in first and repeat revascularisations.

REDUCE-IT was a multicentre, double-blind, placebo-controlled trial, in which statin-treated patients with elevated triglycerides (135–499mg/dL), controlled low density lipoprotein (LDL; 41–100mg/dL), and established cardiovascular disease or diabetes plus risk factors were randomised to receive icosapent ethyl 4g daily or placebo. In the icosapent ethyl arm, the primary composite and other cardiovascular endpoints were substantially reduced. Prespecified analyses examined all coronary revascularisations, recurrent revascularisations, and revascularisation subtypes.

Benjamin Peterson (Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, USA) and colleague stated that they are not are aware of any other non-LDL based therapy that has been shown to reduce coronary artery bypass grafting (CABG) in a blinded, randomised trial. They concluded that many patients who are treated with stents qualify for treatment with icosapent ethyl, adding that screening for eligibility and starting treatment among patients who undergo cardiac stenting either at the time of the initial procedure or during follow-up could result in a large reduction in the need for repeat cardiac stenting or bypass surgery.

Peterson, who is the lead author of the REDUCE-IT REVASC analyses, said: “Prior therapies aimed at patients with elevated triglycerides have not demonstrated a consistent benefit in reducing coronary revascularisation. We were able to show that treating patients with icosapent ethyl who have elevated triglycerides on statin therapy, and who also have either cardiovascular disease or diabetes plus cardiovascular risk factors, resulted in a significant reduction in revascularization, including coronary stenting and cardiac bypass surgery.”

He added: “Overall, there was a 34% reduction in first revascularisation events, and even higher reductions in subsequent revascularisation events among statin-stabilised patients treated with icosapent ethyl versus placebo. There was also a significant 32% reduction in stenting and a 39% reduction in the need for CABG in this double-blind, placebo-controlled trial with independent adjudication of events,” Peterson explained.

Source CardiovascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua google bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua twitter bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua MySpace bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua LinkedIn bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua stumbleupon bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua icio bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua digg bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua yahoo bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua yahoo bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua yahoo bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation Chia sẽ qua yahoo bài: Statin therapy plus icosapent ethyl significantly reduces number first and repeat revascularisation

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP